Coulda, Shoulda? Sanofi's Skip On Portola Proves Clot-Buster Gain For Novartis
This article was originally published in The Pink Sheet Daily
Executive SummaryDeal could complicate venture investors' exit, though Portola thinks not – as another would-be partner eyes second lead product.
You may also be interested in...
Although one day it may compete with Bristol-Myers Squibb and Pfizer in the market for anticoagulant Factor Xa inhibitors, Portola has partnered with the two pharmas to fund a study on its class-wide antidote compound that prevents serious bleeding events.
Without a partner for its anticoagulant in an increasingly complex market, privately-held Portola takes $89 million in late-stage money to conduct Phase III trials on its own.